Back to Journals » Clinical Interventions in Aging » Volume 15

Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient

Authors Makhani A, Thake M, Gibson W

Received 13 November 2019

Accepted for publication 27 March 2020

Published 23 April 2020 Volume 2020:15 Pages 575—581


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Richard Walker

Asad Makhani,1 Miriam Thake,2 William Gibson1

1University of Alberta, Division of Geriatric Medicine, Edmonton, Alberta, Canada; 2Great Western Hospitals NHS Foundation Trust, Swindon SN3 6BB, UK

Correspondence: William Gibson
University of Alberta, Division of Geriatric Medicine, 1-198 Clinical Sciences Building, 11350 83 Ave, Edmonton, Alberta Tel +1 780 248 1969

Abstract: Lower urinary tract symptoms, including urgency, urgency incontinence, frequency, and nocturia, are highly prevalent in older adults and are associated with significant morbidity and impairment in quality of life. When conservative measures such as bladder training fail to improve symptoms, pharmacological management is recommended by national and international guidelines. Mirabegron, an agonist of the β 3 adrenergic receptor, demonstrates similar efficacy to the anticholinergic drugs without the risk of anticholinergic effects, but experience and evidence in the very elderly population are limited. This narrative review examines the current evidence base for mirabegron in very elderly adults.

Keywords: overactive bladder, mirabegron, elderly, ageing, anticholinergic, urinary incontinence

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]